Hello Traders!
The highly anticipated play that we’ve been waiting for is the very exotic CIHN!
CIHN (Caribbean International Holdings, Inc.)
CIHN was enthusiastic a few months back, in March of this year to be exact, to announce that it has decided to focus its effort in the area of Regenerative and Personalized Medicine by providing Adult Stem Cell Incubation and Storage to individuals looking for the potential to protect and ensure their future quality of life.
The company finalized operational agreements that allow CIHN to extract Adult Stem Cells from patients in close proximity to where they live through a network of approved doctors nationwide.
Stem Cell Research Is BIG Business!!
The market is currently estimated to be $3.2 Billion!
This is a HUGE market for a stock that is trading at just $.025.
These stem cells will be stored and available for use as future opportunities arise. Currently there are over 100 diseases and conditions identified worldwide for the use of Adult Stem Cells derived from fat to heal the body.
CIHN has also been working on international Stem Cell services in Dominican Republic to supplement the US operations.
What makes CIHN so seriously hot right now is news that quietly got released on Friday around the market closing that almost nobody heard the news that could possibly go viral by midweek.
I have that press release for CIHN and absolutely have to share it with you right now!
“World-Renown Stem Cell Physician Appointed as Medical
Director for Regenerative BioScience”
SARASOTA, Fla., May 2, 2014 (GLOBE NEWSWIRE) -- Caribbean International Holdings (OTCPK:CIHN) through its subsidiary, Regenerative BioScience, has appointed Dr. Leonel Liriano as its Medical Director.
Leonel Francisco Liriano Espinal is a graduate of the Medical School of Medicine Technical University of Santiago (UTESA). Dr. Liriano has specialized as an intensive care physician at St. Joseph Hospital in the city of Santiago de Chile, and has also been prepared in Clinical Nutrition for Critical Patient in the Auxilio Mutuo Hospital, in the city of Santurce, Puerto Rico, as well as studied Intensive Post-operative Cardiovascular at Cedars Hospital in the City of Miami, Florida and trainings in Neurocritical care in NYU Hospital, New York City.
Twelve years ago while talking to a surgeon who practiced in Germany, Dr. Liriano, who is professor of cardiology and intensive care at the Technological University of Santiago (UTES), became interested in the process of cell therapy and how this could serve as hope to treat diseases without possibility of cure. Since then, Dr. Liriano along with his team of doctors from different specialties has successfully applied the stem cell-based therapy to more than 1000 people. This includes 200 sports figures; with the most prominent being baseball player Bartolo Colon for whom he was the lead physician.
Bartolo Colon was out of baseball for nearly 2 years because of a serious shoulder injury, but returned to the sport and became an All-Star thanks to a stem cell procedure where stem cells were taken from his body and then re-injected into his shoulder by Dr. Liriano. This injury previously may have required surgery to be repaired or the player would be forced into early retirement. This life changing procedure may now have the potential to extend athletes careers and shorten rehabilitation time.
The Dr. Liriano is proud to belong to a generation that has much to offer. He is considered as a dynamic professional and owner of a gift that inspires others to make the most of their potential and one of the pioneers of cell therapy in the City of Santiago. He is convinced that in the not too distant future most diseases will be treated with this therapy.
Steven Swank, Chairman and CEO of Caribbean International Holdings, stated "I have received stem cells myself 3 years ago and am a true believer in its potential after seeing my health improvements. Dr. Liriano shares our vision of helping to improve quality of life and we could not be more excited to have someone with this extensive experience and knowledge in this field join as our Medical Director."
Read The Full Release Here: http://finance.yahoo.com/news/world-renown-stem-cell-physician-210000922.html
About CIHN – Caribbean International Holdings, Inc.
(Current PPS. $.025)
Caribbean International Holdings, Inc. is a holding company for Regenerative Bio Science, Inc ("RBSI"). The Company subsidary RBSI is focused on helping individuals protect and ensure their future quality of life through Adult Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. RBSI's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies for degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.
MARKET OUTLOOK
The technology is changing medicine through new therapies, methods and applications in drug development. Its scope is vast and promising, despite challenges.
The biotechnology industry will develop many products using stem cells and increase revenues there from 2013 to 2022. The R&D pipeline is extensive. Overall world revenue will reach $7.3B in 2014, our report forecasts.
Expansion of the market will result from new stem cell treatments and increased uptake of those technologies in drug development assays.
A diverse pipeline of therapies offers hope for treating many diseases. There are potential cures for diabetes, HIV and dry age-related macular degeneration (AMD).
Stem cell-based innovations tackle cardiovascular disorders, autoimmune diseases, metabolic disorders and many other conditions. Some of the breakthroughs will be a commercial reality by 2022, our investigation predicts.
There are many commercial opportunities in stem cells, with high revenues possible from 2013 to 2022. New products will change medicine. Our report shows you and explains.
In 2013, the stem cell therapies market was valued at over $3.2 billion, consisting almost entirely of revenues from the well-established bone marrow transplantation.
INVESTOR HIGHLIGHTS
CIHN believes the focus of the Company offers the greatest opportunity to shareholders and the health and well-being of all those interested in exploring this exciting new breakthrough.
Stem cell research is a promising area of biotechnology, which holds tremendous potential in rendering investor profits.
CIHN is trading at under $.03 and has been experiencing what looks like a bullish trend in the chart over the past week.
CIHN is involved in an industry that is valued over $3.2B
Major factors driving growth in the market include increasing investments from Governments worldwide. The US currently represents the largest regional market worldwide.
The recent news and the future of CIHN could generate a lot of buzz through the investment community!
Without our report you could miss out on information that you could possibly use. But please, still continue to do your research as well and put CIHN on your radar for Monday!
